Clicky

Redhill Biopharma Ltd.(RDHL) News

Date Title
Oct 1 RedHill Biopharma Secures Opaganib COVID-19 Patent
Oct 1 RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Sep 30 RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
Aug 29 RedHill Biopharma Announces First Half 2024 Business Highlights
Aug 26 RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
Aug 19 Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested
Aug 19 RedHill Announces Positive Obesity and Diabetes Results with Opaganib
Aug 16 RedHill Biopharma Announces Plan to Implement ADS Ratio Change
May 22 Pensioners win £9,000 back in 16-year council tax battle
May 6 RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
Apr 24 RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Apr 10 RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
Apr 8 RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Apr 2 RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Mar 11 RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Mar 5 RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Dec 20 RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Dec 4 RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Nov 27 RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
May 22 RedHill Provides R&D Update